Neopterin is produced by monocytes and is a biomarker for inflammation. We recently found that neopterin induces stromal cells to produce cytokines that suppress erythropoiesis in the bone marrow of mice. Despite this suppression, the peripheral hematocrit values are not decreased. The goal of the present study was to determine whether the maintenance of hematocrit values is caused by a neopterin-induced acceleration of extramedullary erythropoiesis. We examined the effects of intravenously injected neopterin on splenic erythropoiesis in C57BL/6J mice and found a marked increase (259% of the pretreatment level) in the number of splenic erythroid progenitor cells (BFU-E and CFU-E) after a slight temporal decrease in the number of erythroid progenitor cells. These results suggest that neopterin increases splenic erythropoiesis to compensate for the suppression of erythropoiesis in the bone marrow, resulting in the maintenance of hematocrit levels in peripheral blood.
Introduction
Neopterin is a metabolite of guanosine triphosphate that is produced in the biopterin synthetic pathway (1) . Large amounts of this metabolite are generated by monocytes and macrophages in vitro in response to interferon-γ (IFN-γ) (2) . Neopterin production is increased after infection by viruses, bacteria and parasites (3) . Due to its stability in biological fluids, neopterin is used to assess the intensity of cell-mediated immune responses. Numerous studies have established neopterin as an indicator for the onset, progression and outcome of various diseases (4) . Although neopterin inhibits erythropoietin gene expression (5) and erythropoietin production (6) in the kidney, the effect of neopterin on hematopoiesis during inflammation has not been fully elucidated. We have recently found that neopterin is biologically active against hematopoiesis during inflammatory processes (7) (8) (9) (10) (11) . Neopterin stimulates myelopoiesis in the bone marrow while suppressing B lymphopoiesis by inducing cytokine production in stromal cells. Neopterin also enlarges the splenic mast cell progenitor pool (12, 13) . These phenomena are consistent with the hematopoietic response that occurs during inflammatory processes, such as infection. We have also found that intravenously injected neopterin suppresses erythropoiesis in the bone marrow of mice, but it does not decrease the peripheral hematocrit values (14, 15) . These findings raise the question of how peripheral hematocrit values remain unchanged despite the suppression of erythropoiesis in the bone marrow. Erythropoiesis in the bone marrow is primarily homeostatic; however, a rapid expansion of erythropoiesis occurs in the adult spleen in response to acute erythropoietic stress. Therefore, we speculate that neopterin accelerates splenic erythropoiesis to compensate for the suppression of erythropoiesis in the bone marrow. In the present study, we examined this possibility by assessing splenic erythropoiesis after neopterin treatment.
Materials and Methods

Mice
Female C57BL/6J mice (Charles River Japan; Atsugi, Japan) were housed under specific pathogenfree conditions at 24 ± 1°C and 55 ± 10% relative humidity with a 12-h light-dark cycle. Autoclaved tap water and food pellets were provided ad libitum. Experimental protocols involving total 24 laboratorymice were reviewed by a peer review panel, the 
Neopterin administration
Mice received an intravenous injection of neopterin (4.0 mg/kg bw) and were evaluated after 1, 7, 14 and 21 days. As the control, a group of mice was injected with the same volume of PBS containing the same concentration of HCl. Three mice per group were examined for each data point. The serum concentrations of neopterin in pretreated mice and treated mice 30 and 60 min after the intravenous injection of neopterin (4 mg/kg bw) were less than 1 nmol/L, that is, 7,150 nmol/L and 1,720 nmol/L, respectively (12) .
Preparation of spleen cells
Splenic tissue samples were minced in ice-cold α-minimum essential medium (α-MEM; Life Technology, Grand Island, NY, USA) and gently homogenized in a Potter's glass homogenizer to obtain a single-cell suspension.
In vitro colony assays
Erythroid burst-colony-forming units (BFU-E) and erythroid colony-forming units (CFU-E) were assayed by suspending mononuclear cells in α-MEM containing 1% methylcellulose, 30% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 1% deionized bovine serum albumin, 100 µM 2-mercaptoethanol (2-ME), and erythropoietin (Kirin Brewery Co., Tokyo, Japan) at a concentration of 2 U/ml for BFU-E and 0.4 U/mL for CFU-E (14) . IL-3 (1 ng/mL) was added to the medium for BFU-E but not CFU-E. Granulocytemacrophage colony-forming units (CFU-GM) were assayed by suspending mononuclear cells in α-MEM containing 1% methylcellulose, 30% FBS, 1% bovine serum albumin, 1 mM 2-ME, and 10 ng/mL granulocyte-macrophage colony stimulating factor (GM-CSF; R&D, Minneapolis, MN, USA) (18) . Cells (1-mL aliquots) were plated in 35-mm plastic dishes and incubated at 37°C in a fully humidified atmosphere of 5% CO 2 in air. Cell cultures were performed on triplicate plates, and the mean and standard deviation of the mean were calculated to assess the assay quality. BFU-E, CFU-E, and CFU-GM were counted on days 10, 2 and 7, respectively.
Statistical analysis
All data are presented as mean ± standard deviation (SD). The significance of differences among experimental groups was assessed by using one-way analysis variance (ANOVA). The acceptance level of statistical significance was P < 0.05.
Results and Discussion
To determine the in vivo effect of neopterin on erythropoiesis and myelopoiesis in the spleen, neopterin (4.0 mg/kg bw) was intravenously injected into mice, and the number of BFU-E, CFU-E and CFU-GM was determined after 1, 7, 14 and 21 days. Prior to the neopterin injection, the absolute number of BFU-E, CFU-E and CFU-GM in the spleen was 3154 ± 224, 14073 ± 2270, and 1339 ± 136 (mean ± SD), respectively. Figure 1. shows the changes in the number of erythroid progenitor cells (BFU-E and CFU-E) and myeloid progenitor cells (CFU-GM) in the spleen after neopterin injection. The number of BFU-E decreased to 76% of the pretreatment level on day 7, followed by a rapid increase to 259% of the pretreatment level on The change in the number of CFU-E in treated mice was similar to that of BFU-E. In contrast, the number of CFU-GM increased rapidly to 257% of the pretreatment level on day 1, followed by a rapid decrease to 24% on day 7; it maintained a level less than that at pretreatment for the remaining time points. Interestingly, the fluctuations of erythroid-and myeloid-progenitor cells in the spleen of mice treated with neopterin are quite different from those in the bone marrow. Namely, the numbers of erythroid progenitor cells in the spleen were rapidly and markedly increased on day 14, whereas those in the bone marrow were 60% of the pretreatment levels until day 14 (14) . In contrast, the number of myeloid progenitor cells in the spleen was rapidly decreased on day 7, whereas that in the bone marrow was 160% of pretreatment levels until day 7 (14) . These data suggest that neopterin induces erythropoiesis dominance in the spleen and myelopoiesis dominance in the bone marrow. Acute anemia leads to the rapid expansion and differentiation of a specialized population of stress erythroid progenitors that reside in the spleen (19) . Therefore, it seems likely that a specialized population of stress erythroid progenitors in the spleen may compensate for the peripheral erythrocyte depletion caused by erythropoiesis suppression in the bone marrow, resulting in the maintenance of the pretreatment hematocrit level.
The mechanisms by which neopterin differentially affects erythropoiesis in the spleen and the bone marrow remain unknown. The inhalation of nitrous oxide (N 2 O) in mice significantly decreased the numbers of spleen colony-forming units (CFU-S) and CFU-GM in the spleen but not in the bone marrow (20) . The decreased number of hematopoietic cells in the spleen was due to damage in the splenic hematopoietic microenvironment (21, 22) . In contrast, Mori and Kitamura reported that the radioprotective effects of carbon particles or other particulate substances on irradiated mice are more predominant in the spleen than in the bone marrow (23) . These different responses in the bone marrow and spleen were attributable to the different hematopoietic microenvironments. The expansion of a specialized population of stress erythroid progenitors is promoted by cytokines such as BMP4 and stem cell factor (SCF). We recently found that the intravenous injection of neopterin into mice decreased the SCF gene expression in the bone marrow, but increased the SCF gene expression in the spleen (12) . Furthermore, the spleen contains a unique hematopoietic microenvironment that can support expansive erythropoiesis (24) . It seems likely that the differences in the responses of the bone marrow and spleen to neopterin are also attributable to differences in the hematopoietic microenvironment. Stromal cells are essential components of the hematopoietic microenvironment, which is composed of a heterogeneous mixture of mesenchymal cells including fibroblasts, adipocytes, macrophages and endothelial cells. Thus, it is necessary to quantitatively and qualitatively determine the stromal cell type distributed in the spleen and bone marrow.
Zvetkova et al. reported that exogenous addition of neopterin to long-term murine bone marrow culture system resulted in the proliferation and differentiation of stromal/mesenchymal progenitor cell (25) . Furthermore, Kurz et al. reported CD34 + human hematopoietic cells are able to induce neopterin formation and tryptophan degradation upon stimulation with interferon-γ, however, the induction of these biochemical pathways could not suppress erythropoiesis (26) . These data suggest that neopterin is biologically active against stromal cells rather than hematopoietic cells. Further studies are required to elucidate the mechanisms underlying the effects of neopterin, but our present findings provide evidence that neopterin is a potent regulatory factor for splenic erythropoiesis via the activation of the hematopoietic microenvironment during inflammatory processes.
Lastly, regarding the relevance of the findings of the present study to human clinical conditions, because serum neopterin in the steady state in mice is not detected whereas that in humans is inherent, the response to neopterin in murine species might be exaggerated, which could be a limitation. However, data obtained from mice bred under conventional conditions other than data obtained under germ-free conditions were not reported previously. In contrast, the reciprocal clinical conditions of an elevated neopterin concentration associated with low counts of red blood cells and an increase in the number of myelopoietic cells in the bone marrow, are also possible relevant clinical conditions due to the effect of neopterin.
